recalled Genepro Whey 4th Generation Plasma Treated Protein (unflavored) because the product is mislabeled and fails to declare milk as an allergen
Today, we of course discuss the potential side effects and safety concerns of peptides, as well as the critical issue of sourcing clean peptides and working with a board-certified physician if one is going to pursue peptide use
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
Sikiric P, Seiwetht S, Ruckman R, Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implication
And if you need more, our telehealth video visits connect you with a real doctor anytime, anywhere, without the wait
However, similar to Bacteroides species, C
